Last reviewed · How we verify
ChimeriVax™-JE
ChimeriVax-JE is a live attenuated chimeric vaccine that combines the yellow fever vaccine backbone with Japanese encephalitis virus envelope genes to induce protective immunity against Japanese encephalitis.
ChimeriVax-JE is a live attenuated chimeric vaccine that combines the yellow fever vaccine backbone with Japanese encephalitis virus envelope genes to induce protective immunity against Japanese encephalitis. Used for Japanese encephalitis prevention in endemic regions.
At a glance
| Generic name | ChimeriVax™-JE |
|---|---|
| Sponsor | Sanofi |
| Drug class | Live attenuated chimeric vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a recombinant approach where the structural genes of Japanese encephalitis virus are inserted into an attenuated yellow fever vaccine (17D) backbone. This chimeric construct allows the vaccine to stimulate both humoral and cellular immune responses against Japanese encephalitis virus while maintaining the safety profile of the yellow fever vaccine platform. The resulting vaccine provides protection against Japanese encephalitis infection through neutralizing antibody production and T-cell mediated immunity.
Approved indications
- Japanese encephalitis prevention in endemic regions
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines (PHASE3)
- Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children (PHASE2)
- Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. (PHASE3)
- A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX (PHASE3)
- Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine (PHASE2)
- Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) (PHASE2)
- Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age (PHASE2)
- A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChimeriVax™-JE CI brief — competitive landscape report
- ChimeriVax™-JE updates RSS · CI watch RSS
- Sanofi portfolio CI